title: Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement.
authors.affiliation: Division of Hematology and Bone Marrow Transplantation, Azienda Ospedaliero-Universitaria di Udine, Udine, Italy, mario.tiribelli@uniud.it.
authors.forename: Mario
authors.initials: M
authors.lastname: Tiribelli
authors.forename: Daniela
authors.initials: D
authors.lastname: Barraco
authors.forename: Marta
authors.initials: M
authors.lastname: Medeot
authors.forename: Luciana
authors.initials: L
authors.lastname: Marin
authors.forename: Emanuela
authors.initials: E
authors.lastname: Ottaviani
authors.forename: Federico
authors.initials: F
authors.lastname: De Marchi
authors.forename: Daniela
authors.initials: D
authors.lastname: Damiani
authors.forename: Renato
authors.initials: R
authors.lastname: Fanin
mesh_terms: D000368:Aged; D001549:Benzamides / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D009196:Myeloproliferative Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D017211:Treatment Failure; D016896:Treatment Outcome; D000097764:ETS Translocation Variant 6 Protein
chemical_list: D001549:Benzamides; D000068877:Imatinib Mesylate; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011505:Protein-Tyrosine Kinases; D011743:Pyrimidines; C426234:TEL-ABL fusion protein, human; D000097764:ETS Translocation Variant 6 Protein; C498826:nilotinib